Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Novartis (NVS) through the VizualStocks API.
Novartis core net income per weighted-average ordinary share on a basic basis, after the issuer’s non-IFRS core adjustments and tax effects. This is basic ordinary-share EPS, rather than diluted EPS.
coreBasicEpsNovartis core operating income divided by net sales to third parties. The non-IFRS core measure excludes amortization, impairment, acquisition and other items identified in the issuer reconciliation.
coreOperatingMarginWorldwide net sales to third parties for Cosentyx, a medicine in Novartis’s immunology portfolio. Amounts use reported US dollars and exclude constant-currency growth calculations.
cosentyxNetSalesWorldwide net sales to third parties for Entresto, a medicine in Novartis’s cardiovascular, renal and metabolic portfolio. Amounts use reported US dollars and exclude constant-currency growth calculations.
entrestoNetSalesWorldwide net sales to third parties for Kesimpta, a medicine in Novartis’s neuroscience portfolio. Amounts use reported US dollars and exclude constant-currency growth calculations.
kesimptaNetSalesWorldwide net sales to third parties for Kisqali, a medicine in Novartis’s oncology portfolio. Amounts use reported US dollars and exclude constant-currency growth calculations.
kisqaliNetSalesWorldwide net sales to third parties for Leqvio, a medicine in Novartis’s cardiovascular, renal and metabolic portfolio. Amounts use reported US dollars and exclude constant-currency growth calculations.
leqvioNetSalesWorldwide net sales to third parties for Pluvicto, a medicine in Novartis’s oncology portfolio. Amounts use reported US dollars and exclude constant-currency growth calculations.
pluvictoNetSalesWorldwide net sales to third parties for Scemblix, a medicine in Novartis’s oncology portfolio. Amounts use reported US dollars and exclude constant-currency growth calculations.
scemblixNetSales